Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M2,172Revenue $M13.9Net Margin (%)-164.1Z-Score9.8
Enterprise Value $M1,967EPS $-1.2Operating Margin %-244.2F-Score0
P/E(ttm))0Cash Flow Per Share $0Pre-tax Margin (%)-169.6Higher ROA y-yN
Price/Book5.510-y EBITDA Growth Rate %0Quick Ratio10.5Cash flow > EarningsN
Price/Sales50.95-y EBITDA Growth Rate %0Current Ratio10.5Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-8.3Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)8ROE % (ttm)-10.6Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M98.8ROI % (ttm)-110.7Gross Margin Increase y-yN

Gurus Latest Trades with XON

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
XONDaniel Loeb 2014-03-31 Add0.18%$22.5 - $36.82
($28.82)
$ 21.98-24%Add 18.15%3,000,000
XONDaniel Loeb 2013-12-31 Add0.15%$17.65 - $25.5
($21.05)
$ 21.984%Add 18.07%2,539,200
XONDaniel Loeb 2013-09-30 Buy 1.2%$21.36 - $29.7
($24.16)
$ 21.98-9%New holding, 2150592 sh.2,150,592
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

XON is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
XON Daniel Loeb 2014-03-313,000,0003.041.2+18.15%
Premium Most recent portfolio changes are included for Premium Members only!


XON: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
KIRK RANDAL JCEO, 10% Owner 2014-05-13Buy65,173$15.1944.7view
Reed Thomas D.Chief Science Officer 2014-05-13Buy640$15.640.9view
Lehr Donald P.Chief Legal Officer 2014-05-13Buy1,850$15.9937.46view
Huang KellySVP-Consumer Sector 2014-05-09Buy3,200$15.7839.29view
Kasser Thomas R.SVP--Food Sector 2014-05-09Buy10,000$13.3964.15view
Krishnan Krish SCOO 2014-05-09Buy20,900$14.2154.68view
Krishnan SumaSVP--Product Development 2014-05-09Buy20,900$14.2154.68view
KIRK RANDAL JCEO, 10% Owner 2014-05-09Buy67,333$15.1644.99view
KIRK RANDAL JCEO, 10% Owner 2014-03-27Buy243,001$25.72-14.54view
Frost Gregory IanSVP--Health Sector 2014-03-04Buy100,000$25.95-15.3view

Press Releases about XON :

    Quarterly/Annual Reports about XON:

    News about XON:

    Articles On GuruFocus.com
    5-Year Lows: American Eagle Outfitters, Intrexon Corp, Mack-Cali Realty Corp, and Weight Watchers In Apr 20 2014 
    Daniel Loeb Comments on Intrexon Corporation Jan 22 2014 
    Daniel Loeb Lags S&P But Top New Stocks Advance Jan 07 2014 
    David Einhorn’s New Stocks – TPX, XON, NVR Nov 14 2013 
    Weekly CEO Buys Highlight: XON, ARCP, FSFR, CNTY, RHP Aug 18 2013 

    More From Other Websites
    Soligenix Receives Additional NIAID Funding to Advance Development of OrbeShield™ in GI ARS Aug 01 2014
    Soligenix Receives Additional NIAID Funding to Advance Development of OrbeShield™ in GI ARS Aug 01 2014
    Intrexon Enters into Technology Collaboration to Advance Animal Health Applications Jul 29 2014
    Intrexon Enters into Technology Collaboration to Advance Animal Health Applications Jul 29 2014
    ZIOPHARM Announces Expansion of Ground-Breaking Synthetic Immuno-Oncology Programs With Intrexon and... Jul 22 2014
    ZIOPHARM Announces Expansion of Ground-Breaking Synthetic Immuno-Oncology Programs With Intrexon and... Jul 22 2014
    ZIOPHARM Announces Expansion of Ground-Breaking Synthetic Immuno-Oncology Programs With Intrexon and... Jul 22 2014
    Synthetic Biologics' Academic Collaborator to Present Novel Monoclonal Antibody Combination for... Jul 21 2014
    Soligenix Announces Combination Vaccine for Ricin and Anthrax Achieves Simultaneous Protection Jul 09 2014
    INTREXON CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD... Jul 03 2014
    Why Intrexon (XON) Stock Is Gaining Today Jul 02 2014
    Intrexon to Acquire Trans Ova Genetics Jul 01 2014
    Intrexon to Acquire Trans Ova Genetics Jul 01 2014
    Intrexon's Industrial Products Division Achieves Bioconversion of Methane to Farnesene Jun 30 2014
    The Sirens Of Ziopharm Jun 15 2014
    INTREXON CORP Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters... Jun 13 2014
    Vista Partners Updates Coverage on Soligenix, Inc. (Ticker: SNGX); $5.50 Price Target Jun 11 2014

    Add Notes, Comments or Ask Questions

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK
    Email Hide